Brief: Tenaya Therapeutics Announces TN-201 IND Clearance And Anticipated 2023 Milestones
09/01/2023 13:39
Jan 9 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS ANNOUNCES TN-201 IND CLEARANCE AND
ANTICIPATED 2023 MILESTONES
* TENAYA THERAPEUTICS INC - PHASE 1B CLINICAL TRIAL FOR
TN-201 IN
MYBPC3-ASSOCIATED HCM PATIENTS EXPECTED TO BEGIN DOSING IN Q3
2023
* TENAYA THERAPEUTICS INC - DATA FROM FIRST-IN-HUMAN
CLINICAL
TRIAL OF TN-301 ANTICIPATED IN SECOND HALF 2023
* TENAYA THERAPEUTICS INC - TN-401 IND SUBMISSION PLANNED IN
SECOND HALF 2023
* TENAYA THERAPEUTICS INC - CASH RUNWAY EXTENDED INTO FIRST
HALF
2025
* TENAYA THERAPEUTICS INC - ENDED THIRD QUARTER OF 2022 WITH
$149.5 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS IN
MARKETABLE SECURITIES
Source text for Eikon: ID:nGNX5RBBXV
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027